MANGOCEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Mangoceuticals, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(Unaudited)
| For The Three Months | For The Three Months | For The Nine Months | For The Nine Months | |
|---|---|---|---|---|
| Ended | Ended | Ended | Ended | |
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |
| Revenues | ||||
| Revenues | $133,368 | $245,160 | $510,626 | $487,119 |
| Cost of revenues | 21,505 | 52,193 | 71,965 | 101,538 |
| Cost of revenues - related party | 29,192 | 48,378 | 138,800 | 96,663 |
| Gross profit | 82,671 | 144,589 | 299,861 | 288,918 |
| Operating expenses | ||||
| General and administrative expenses | 523,855 | 544,960 | 2,146,517 | 2,496,574 |
| Salary and benefits | 242,941 | 271,466 | 795,255 | 667,560 |
| Advertising and marketing | 251,330 | 720,531 | 1,332,957 | 1,633,528 |
| Investor relations | 255,000 | 255,500 | 438,000 | 774,965 |
| Stock based compensation | 567,619 | 151,592 | 1,881,464 | 1,367,134 |
| Total operating expenses | 1,840,745 | 1,944,049 | 6,594,193 | 6,939,761 |
| Loss from operations | (1,758,074) | (1,799,460) | (6,294,332) | (6,650,843) |
| Other expense | ||||
| Imputed interest - related party | - | - | - | (6,473) |
| Interest expense - amortization on discount | 241,620 | - | 464,298 | - |
| Total other expense | 241,620 | - | 464,298 | (6,473) |
| Loss before income taxes | (1,999,694) | (1,799,460) | (6,758,630) | (6,644,370) |
| Income taxes | - | - | - | - |
| Net loss | (1,999,694) | (1,799,460) | (6,758,630) | (6,644,370) |
| Net loss attributed to non-controlling interest | (461) | - | (837) | - |
| Net loss attributed to Mangoceuticals, Inc. | (1,999,233) | (1,799,460) | (6,757,793) | (6,644,370) |
| Basic and diluted loss per share | ||||
| Basic and diluted loss per share | $(0.99) | $(1.70) | $(3.83) | $(6.68) |
| Weighted average number of shares * | ||||
| Basic and diluted* | 2,013,848 | 1,061,572 | 1,765,051 | 994,897 |
| * | Shares and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.